Randomised studies of cetuximab combined with chemotherapy in the first-line treatment of colorectal cancer clearly showed that the benefit of adding cetuximab was limited to K-ras wild-type cancers (Bokemeyer et al, 2008; Van Cutsem et al, 2008). The gene discussed is KRAS; the disease is colorectal cancer.